Paravalvular leak will be one of the secondary endpoints in our early feasibility study.
And to follow-up on how confusing the different comparisons done by different companies, Dr Meduri in the webcast in Sept said for the 23mm valve, the Sapien is generally benchmarked at an EOA of 1.45 cm squared and the Evolut is about a 1.84, with the DurAVR at a 2. So it looks to me like the Abbott website is rounding up their numbers.Not sure if they rounded up their device but maybe they did and their actual EOA is below a 2 (provided that is for the 23 mm Abbott device, their website does not confirm that).
- Forums
- ASX - By Stock
- AVR
- Competitor FDA approval
Competitor FDA approval, page-11
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.00 |
Change
-0.190(1.56%) |
Mkt cap ! $253.6M |
Open | High | Low | Value | Volume |
$12.00 | $13.06 | $11.75 | $459.6K | 38.05K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 5792 | $12.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.70 | 3000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 5792 | 12.000 |
2 | 5500 | 11.880 |
2 | 520 | 11.600 |
2 | 1425 | 11.500 |
1 | 80 | 11.250 |
Price($) | Vol. | No. |
---|---|---|
12.700 | 3000 | 1 |
13.000 | 4000 | 2 |
13.300 | 2000 | 1 |
14.300 | 200 | 1 |
14.400 | 366 | 1 |
Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |